Biosimilar Candidate CT-P42 in Diabetic Macular Edema: 24-Week Results from a Randomized, Active-Controlled, Phase III Study. Journal Abstract

Biosimilar Candidate CT-P42 in Diabetic Macular Edema: 24-Week Results from a Randomized, Active-Controlled, Phase III Study.

Publication Date: 2024 Dec

Full Text Sources

Authors

Sebastian Wolf; Paulo-Eduardo Stanga; Milan Veselovsky; Miroslav Veith; Andras Papp; Shobhana Mange; Lakshmi Kanta Mondal; Dominika Romanczak; Ladislav Janco; Rohan Chauhan; Bożena Romanowska-Dixon; Alena Eremina; Nataliya Zavgorodnya; Jaroslava Dusova; Min Sagong; Sunghyun Kim; Keumyoung Ahn; Suyoung Kim; Youngmin Bae; Sangmi Lee; Hyejin Kang; David M Brown

Abstract

OBJECTIVE

To demonstrate the therapeutic similarity of CT-P42 compared with reference aflibercept (Eylea) in adult patients with diabetic macular edema (DME).

Source

Ophthalmology. Retina

Pub Types(s)

Journal Article

Language

English

PubMed ID

38942386